WebMargenza is indicated, in combination with chemotherapy, for the treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer … WebThe efficacy and safety of MARGENZA plus chemotherapy compared with trastuzumab plus chemotherapy was evaluated in SOPHIA, a randomized, multicenter, open-label trial of 536 metastatic HER2-positive breast cancer patients † who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Margenza (Margetuximab-cmkb Injection, for Intravenous Use
WebDec 16, 2024 · The approval was based on safety and efficacy results from the pivotal Phase 3 SOPHIA trial. “The approval of MARGENZA is an exciting milestone for MacroGenics and, more importantly, it brings a ... WebThe second-generation anti-human epidermal growth factor receptor2 protein (HER2) monoclonal antibody margetuximab (MARGENZA™, margetuximab-cmkb) is being … fiat halloween
Efficacy of Margetuximab vs Trastuzumab in Patients With ... - PubMed
WebSep 8, 2024 · Published: Sept. 8, 2024 By Ellen Bombela BioSpace Trastuzumab stood its ground against MacroGenics ’ MARGENZA treatment in a recent late-stage trial. On Tuesday, the biopharmaceutical company announced the final overall survival (OS) analysis of its SOPHIA Phase III study in adults with metastatic HER2-positive breast cancer. WebSep 9, 2024 · Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. ... WebDec 16, 2024 · The SOPHIA study (NCT02492711) is a randomized, open-label Phase 3 clinical trial evaluating MARGENZA plus chemotherapy compared to trastuzumab plus … fiat halland